Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit

Clinical Neuropharmacology

Volumn 31, Issue 6, 2008, Pages 319-332

  Lerma Carrillo, Ivan ^a,b   De Pablo Brühlmann, Silvia ^a   Del Pozo, Marta Leonor ^a   Pascual Pinazo, Fernando ^a   Molina, Juan D ^a   Baca García, Enrique ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Hospital Dr Rodríguez Lafora   (Spain)

Author keywords

Antipsychotics; Polypharmacy; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AMBULATORY CARE; ARTICLE; CLINICAL TRIAL; DISEASE CLASSIFICATION; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; PARANOID SCHIZOPHRENIA; POLYPHARMACY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC DEPARTMENT; RESIDUAL SCHIZOPHRENIA; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREMOR; DRUG COMBINATION; LENGTH OF STAY; PSYCHOSIS;

ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LENGTH OF STAY; MALE; POLYPHARMACY; PSYCHIATRIC DEPARTMENT, HOSPITAL; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 59849106594     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31815cba78     Document Type: Article

References (104)

1. Kane JM, Leucht S, Carpenter D, et al. Treatment of schizophrenia 1999. The expert consensus guideline series. J Clin Psychiatry 2003;64(suppl 12).
2. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(suppl 2):1-56.
3. Miller AL, Crismon ML, Rush AJ, et al. The Texas medication algorithm project: clinical results for schizophrenia. Schizophr Bull 2004;30(3): 627-647.
4. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004; 30(2):193-217.
5. Available at: http://www.schizophreniaguidelines. co.uk/.
6. Heresco-Levy U, Greenberg D, Wittman L, et al. Prescribing patterns of neuroactive drugs in 98 schizophrenic patients. Isr J Psychiatry Relat Sci 1989;26(3):157-163.
7. Kiivet RA, Llerena A, Dahl ML, et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br J Clin Pharmacol 1995;40(5):467-476.
8. Ungvari GS, Pang AH, Chiu HF, et al. Psychotropic drug prescription in rehabilitation. A survey in Hong Kong. Soc Psychiatry Psychiatr Epidemiol 1996;31(5):288-291.
9. Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999;53(suppl):S35-S40.
10. Rittmannsberger H, Meise U, Schauflinger K, et al. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999;14(1): 33-40.
11. Wang PS, West JC, Tanielian T, et al. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 2000;26(2):451-457.
12. Fourrier A, Gasquet I, Allicar MP, et al. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 2000; 49(1):80-86.
13. Procyshyn RM, Kennedy NB, Tse G, et al. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001;46(4):334-339.
14. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York metropolitan region. Schizophr Bull 2002; 28(1):31-42.
15. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002;28(1):17-29.
16. Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002;28(1):75-84.
17. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003;64(9):984-989.
18. Florez Menendez G, Blanco Ramos M, Gomez-Reino Rodriguez I, et al. Polipharmacy in the antipsychotic prescribing in practices psychiatric out-patient clinic. Actas Esp Psiquiatr 2004;32(6):333-339.
19. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65(10):1377-1388.
20. Sim K, Su A, Fujii S, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004;58(2):178-183.
21. Janssen B, Weinmann S, Berger M, et al. Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 2004;30(4): 1023-1033.
22. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005;5(1):26.
23. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005;187:243-247.
24. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine a double-blind placebo-controlled study. Br J Psychiatry 1997;171:569-573.
25. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66(1):63-72.
26. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162:130-137.
27. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354:472-482.
28. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-397.
29. Taylor CG, Flynn SW, Altman S, et al. An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 2001;48:155-158.
30. De Groot IW, Heck AH, van Harten PN. Addition of risperidone to clozapine therapy in chronically psychotic impatiens. J Clin Psychiatry 2001;62: 129-130.
31. Agelink MW, Ullrich H. Clozapine combined with amisulpride for refractory schizophrenia. Am J Psychiatry 2004;161:924-925.
32. Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially response to clozapine. Acta Psychiatr Scand 2004;110:292-298.
33. Ziegenbein M, Sieberer M, Kuenzel HE, et al. Augmentation of clozapine with amisulpride in patients with treatment-resistant schizophrenia: an open clinical study. German J Psychiatry 2006;9:17-21.
34. Kaye SK. Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 2003;64:215-216.
35. Ziengenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol 2005;28:220-224.
36. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006;113: 142-147.
37. Ziegenbein M, Wittmann G, Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Invest 2006;26:117-124.
38. Raskin S, Durst R, Katz G, et al. Olanzapine and sulpiride: a preliminary study of combination/ augmentation in patients with treatment-resistant schizophrenia. J Clin Psychopharmacol 2000;20: 500-503.
39. Kotler M, Strous RD, Reznik I, et al. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 2004;19:23-26.
40. Tyson SC, Devane CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 1995;152:1401-1402.
41. Risch SC, Jackson C, Ware M, et al. Case reports of combined clozapine and risperidone pharmacotherapy: pharmacokinetic and pharmacodynamics interactions. Paper presented at: American College of Neuropsychopharmacology, 33rd Annual Meeting ACNP; December 16, 1994; San Juan, Puerto Rico.
42. Morera AL, Barreiro P, Cano-Muñoz JL. Risperidone and clozapine combination for treatment of refractory schizophrenia. Acta Psychiatr Scand 1999;99:305-307.
43. Zervas IM, Mantonakis I, Catan K. Risperidone-clozapine combination for refractory schizophrenia. Psychopharmacology 1998:S37.
44. Adesanya A, Pantelis C. Adjunctive risperidone treatment in patients with "clozapine-resistant schizophrenia". Aust NZ J Psychiatry 2000;34: 533-534.
45. Raju Kumar R, Khanna S. Clozapine-risperidone combination in treatment-resistant schizophrenia. Aust NZ J Psychiatry 2001;35:543.
46. Raskin S, Katz G, Zislin Z, et al. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 2000;101: 334-336.
47. McCartthy RH, Terkelsen KG. Risperidone augmentation of clozapine. Pharmacopsychiatry 1995;28:61-63.
48. Chong SA, Tan CH, Lee HS. Hoarding and clozapine-risperidone combination. Can J Psychiatry 1996;41:315-316.
49. Patel JK, Salzman C, Green AL, et al. Chronic schizophrenia: response to clozapine, risperidone and paroxetine. Am J Psychiatry 1997;154: 543-546.
50. Mantonakis I, Kattan K, Zervas IM. Risperidone augmentation of clozapine and olanzapine for refractory schizophrenia. Eur Neuropsychopharmacol 1998;8(suppl 2):233.
51. Lerma-Carrillo I, Molina JD, Cuevas-Duran T, et al. Adjunctive treatment with risperidone in clozapine resistant schizophrenia: a case report and review. Clin Neuropharmacol 2007;30(2): 114-121.
52. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998;10:113-115.
53. Rhoads E. Polypharmacy of two atypical antipsychotics. J Clin Psychiatry 2000;61: 678-680.
54. Zink M, Mase E, Dressing H. Ziprasidone-augmentation of clozapine. Psychiatr Prax 2004;31:259-269.
55. Zink M, Mase E, Dressing H. Combination of ziprasidone and clozapine in treatment resistant schizophrenia. Hum Psychopharmacol 2004;19: 271-273.
56. Ziegenbein M, Callies IT. Cloapine nad Ziprasidone: A useful combination in patients with treatment-resistant schizophrenia. J Neuropsychitr Clin Neurosci 2006;18: 246-247.
57. Matthiasson P, Costa DC, Erlandsson K, et al. Increased dopamine D2 receptor binding in the basal ganglia after augmenting clozapine treatment with amisulpride. An 123-I-IBZM SPECT study. J Psychopharmacol 2000; 14(3 suppl):A57.
58. Matthiasson P, Costa DC, Erlandsson K, et al. The relationship between dopamine D2 receptor occupancy and clinical response in amisulpride augmentation of clozapine non-response. J Psychopharmacol 2001; 15(3 suppl):A41.
59. Matthiasson P, Costa DC, Erlandsson K, et al. Amisulpride augmentation of clozapine and striatal dopamine D2 receptor binding potential. A 123-I-IBZM SPET study. Schizophr Res 2002; 53(3 suppl):208-209.
60. Matthiasson P, Munro JC, Travis MJ, et al. Amisulpride augmentation of clozapine effect in patients with treatment resistant schizophrenia. Schizophr Res 2002;53(suppl):209.
61. Croissant B, Hermann D, Olbrich R. Saving potential of clozapine due to combination with amisulpride. Psychopharmakotherapie 2001;8: 128-130.
62. Agelink MW, Ullrich H. Clozapine combined with amisulpride in the treatment refractory schizophrenia. World J Biol Psychiatry 2001; 2(suppl 1):311S-312S.
63. Ziegenben M, Rosenthal O, Garlipp P. Coadministration of clozapine and amisulpride in psychotic patients. Eur Psychiatry 2002;17 (suppl 1):99S.
64. Ziegenben M, Rosenthal O, Machleidt W. Coadministration of clozapine and amisulpride in patients with schizophrenia. Biol Psychiatry 2003;53:48S.
65. Cook B, Hoogenboom G. Combined use of amisulpride and clozapine for patients with treatment resistant schizophrenia. Australas Psychiatry 2004;12:74-76.
66. Zink M, Knopf U, Henn FA, et al. Combination of clozapine and amisulpride in treatment-resistant schizophrenia schizophrenia - case reports and review of the literature. Pharmacopsychiatry 2004;37:26-31.
67. Ḱampf P, Agelink MW, Mass R, et al. Amisulpride in addition to clozapine: a retrospective study indicates improved efficacy and good tolerability. German J Psychiatry 2003;6:64-68.
68. Ḱampf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005;38-40.
69. Croissant B, Hermann D, Olbrich R. Reduction of side effects by combining clozapine with amisulpride: case review and short review of clozapine-induced hypersalivation. A case report. Pharmacopsychiatry 2005;38:38-39.
70. Lim S, Pralea C, Schnitt J, et al. Possible increased efficacy of low-dose clozapine when combined with aripiprazole. J Clin Psychiatry 2004;65: 1284-1285.
71. DeQuardo JR. Increased efficacy with addition of clozapine to aripiprazole. J Clin Psychiatry 2005; 66:396.
72. Ziegenbein M, Sieberer M, Callies IT. Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. Aust N Z J Psychiatry 2005;39:840.
73. Karunakanan K, Tungaraza TE, Harbone G. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 2007;191: 82-83.
74. Clarke LA, Lindenmanyer JP, Kanshik S. Clozapine augmentation for negative symptoms. J Clin Psychiatry 2006;67:675-676.
75. Rocha FL, Hara C. Benefits of combining aripiprazole to clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2006;30: 1167-1169.
76. Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment resistant schizophrenic psychoses. Eur Psychiatry 2004;19:56-58.
77. Zink M. Augmentation of olanzapine in treatment-resistant schizophrenia. J Psychiatr Neurosci 2005;30:409-415.
78. Thome J, Zink M, Knopf U, et al. Combination of olanzapine and amisulpride in treatment resistant schizophrenic psychoses. Int J Neuropsychopharmacol 2002;5(suppl 1):S76.
79. Pedrosa Gil F, Schneider C, Grohmann R. Incompatibility of olanzapine and amisulpride in multisystematic myotonic myopathy. Nervenartz 2001;72:729-733.
80. Lerner V, Chudakova B, Kravets S, et al. Combined use of risperidone and olanzapine in treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol 2000;23:284-286.
81. Mantonakis I, Kattan K, Zervas IM. Risperidone augmentation of clozapine and olanzapine for refractory schizophrenia. Eur Neuropsychopharmacol 1998;8(suppl 2):233.
82. Chue P, Welch R, Snaterse M. Combination risperidone and quetiapine therapy in refractory schizophrenia. Can J Psychiatry 2001;46:86-87.
83. Bozikas VP, Deseri CH, Pitsavas S, et al. Antiaggressive action of combined risperidone and quetiapine in a patient with schizophrenia. Can J Psychiatry 2003;48:426-427.
84. Lerner V, Bergman J, Borokhov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005;28: 66-71.
85. Duggal HS. Aripiprazole-olanzapine combination for treatment of schizophrenia. Can J Psychiatry 2004;49(2):151.
86. Minov C. Risk of QTc prolongation due to combination of ziprasidone and quetiapine. Psychiatr Prax 2004;31(suppl 1):142-144.
87. Dunkley MJ, Reveley MA. Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with prolactin secreting pituitary microadenoma. J Psychopharmacol 2005;19:97-101.
88. Stubbs JH, Haw CM, Staley CJ, et al. Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine. Acta Psychiatr Scand 2000;102:390-393.
89. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8:193-197.
90. Cooke C, De Leon J. Adding other antipsychotics to clozapine. J Clin Psychiatry 1999;60:710.
91. Goos JB. Concomitant use of thioridazine with risperidone. Am J Health Syst Pharm 1995;53:443.
92. Bacher NM, Kaup BA. Combining risperidone with standard neuroleptics for refractory schizophrenia patients. Am J Psychiatry 1996;53:137.
93. Terao T, Kojima H. Risperidone addition and psychotic exacerbation. J Neuropsychiatr Clin Neurosci 2001;13:114-115.
94. Witz S, Kosov I, Assael-Amini M, et al. A more favorable clinical outcome with sulpiride augmentation in a patient with chronic schizophrenia partially responsive to olanzapine. Eur Neuropsychopharmacol 2000;10(suppl 3): 284.
95. Waring EW, Devin PG, Dewan V. Treatment of schizophrenia with antipsychotics in combination. Can J Psychiatry 1999;44:189-190.
96. Voirol P, Robert PA, Meister P, et al. Psychotropic drug prescription in a psychiatric university hospital. Pharmacopsychiatry 1999;32:29-37.
97. Schmidt LG, Niemeyer R, Muller-Oerlinghausen B. Drug prescribing pattern of a psychiatry university hospital in Germany. Pharmacopsychiatry 1983; 16:35-42.
98. Edwards S, Kumar V. A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital. Br J Psychiatry 1984;145:502-507.
99. Stahl S. Antipsychotic agents. In: Essential Psychopharmacology. 2nd ed. Cambridge: Cambridge University Press; 2000:401-458.
100. Scatton B, Claustre Y, Cudennec A. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 1997;12(suppl 2): 29-36.
101. Leucht S. Amisulpride: a selective dopamine antagonist and atypical antipsychotic: results of meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2004;7(suppl 1):15-20.
102. Convit A, Isay D, Otis D, et al. Characteristics of repeatedly assaultive psychiatric inpatients. Hosp Commun Psychiatry 1990;41:1112-1115.
103. Owen C, Tarantello C, Jones M. Repetitively violent patients in psychiatric units. Psychiatr Serv 1998;49:1458-1461.
104. Villagran JM, Luque R. Asociación de antipsíc óticos en la práctica clínica: una revisión crítica. 1st ed. Proas Science, 2007:55.